ライフサイエンスコーパス: IL-6 receptor

1 f the nonsignaling gp80 alpha-subunit of the IL-6 receptor.

2 only when it was in complex with the soluble IL-6 receptor.

3 gp130, the signal-transducing subunit of the IL-6 receptor.

4 ndothelial cells through a newly constituted IL-6 receptor.

5 on in hepatic cells is equivalent to that of IL-6 receptor.

6 ression of the plasma membrane high-affinity IL-6 receptor.

7 e formation of complexes of IL-6 and soluble IL-6 receptor.

8 pression of CD27, and high levels of IgM and IL-6 receptor.

9 ulation and IL-6-induced endocystosis of the IL-6 receptor.

10 increase in the expression of high-affinity IL-6 receptors.

11 ilizumab directed against the interleukin 6 (IL-6) receptor.

12 IL-6 effect was abrogated by excess soluble IL-6 receptor (500 microg/l).

13 6 were mediated by complexation with soluble IL-6 receptor, a process known as trans-signaling.

14 veral factors, including interleukin (IL)-1, IL-6, receptor activator of NF-kappaB (RANK) ligand, par

15 demonstration of increased expression of the IL-6 receptor after loss of sex steroids provides an exp

16 the non-signaling membrane-bound or soluble IL-6 receptor alpha (IL-6R, sIL-6R), which is referred t

17 ted mice with deletion of the membrane bound IL-6 receptor alpha (IL-6Ralpha) on neural cells, on per

18 The association of IL-6 and IL-6 receptor alpha (IL-6Ralpha) with asthma was reporte

19 nstrate that T cell-specific deletion of the IL-6 receptor alpha chain (IL-6Ralpha) results in impair

20 ignal transducer but is not dependent on the IL-6 receptor alpha subunit (IL-6R, gp80) that is requir

21 reduction in the amount of mRNA encoding the IL-6 receptor alpha subunit and IL-6 binding activity.

22 requirement for transcription is the soluble IL-6 receptor alpha, which translocates to endothelial c

23 Using their IL-6 receptor alpha-chain (IL-6Ralpha), Sirpalpha(+) DCs

24 n lower expression of the genes encoding the IL-6 receptor alpha-chain (Il6ra) and the IL-6 signal tr

25 nor O-linked glycosylation is necessary for IL-6 receptor alpha-dependent binding to gp130 or signal

26 ot an agonist for this, but we found soluble IL-6 receptor alpha-subunit (IL-6Ralpha), with their con

27 Diminished hepatitis in IL-6-deficient, anti-IL-6 receptor alpha-treated, ovariectomized, or male mic

28 nstruct a model of IL-6 interacting with the IL-6 receptor (alpha-chain) and gp130 (beta-chain) that

29 cing chain by IL-6 and a soluble form of the IL-6 receptor-alpha (sIL-6Ralpha) binding subunit.

30 romal cells acted cooperatively with soluble IL-6 receptor-alpha and thermally induced gp130 to promo

31 r both lymphoid and myeloid fates, expressed IL-6 receptor-alpha chain and responded to IL-6 by phosp

32 scular adhesion were induced by IL-6/soluble IL-6 receptor-alpha fusion protein in mouse tumors and p

33 g pathway, including increased expression of IL-6 receptor-alpha/gp80, activation of the signal trans

34 edly induced mIndy transcription through the IL-6 receptor and activation of the transcription factor

35 F in the peritoneum, do not bear the cognate IL-6 receptor and are thus unable to respond to classic

36 ean winter, with increased levels of soluble IL-6 receptor and C-reactive protein, risk biomarkers fo

37 ction of IL-6 with concomitant expression of IL-6 receptor and gp130 suggest that these factors may p

38 could be rescued by the addition of soluble IL-6 receptor and IL-6 or by retroviral transduction of

39 toplasmic domain of the gp130 subunit of the IL-6 receptor and is different from the SH2 domain-conta

40 omatin, but did not affect the expression of IL-6 receptor and phosphorylation of JAK/STAT3, MAPK, an

41 lassic signaling using the membrane-anchored IL-6 receptor and trans-signaling using its soluble form

42 Here we demonstrate loss of interleukin 6 (IL-6) receptor and IL-6-responsive colony-forming units

43 blotting; however, lower production of both IL-6-receptor and Stat3 explains, in part, reduced activ

44 The OPC cell lines used express the IL-6 receptor, and IL-6 stimulation of these cells cause

45 IL-6, IL-6 receptor, and phospho-signal transducer and activat

46 s of the gp130 subunit of the interleukin-6 (IL-6) receptor, and a seven amino acid STAT1 recruitment

47 d soluble IL-1 receptor II; IL-6 and soluble IL-6 receptor; and IL-10.

48 nhibition (atacicept) and IL-6 as opposed to IL-6 receptor antagonism, have also been evaluated.

49 cytokine in the toxicity response, using the IL-6 receptor antagonist tocilizumab.

50 specific antibodies, IL-12/23 antibodies, an IL-6 receptor antagonist, a sphingosine-1-phosphate agon

51 rmeabilized osteoclasts incubated with anti- IL-6 receptor antibodies revealed intense, strictly peri

52 d this toxicity was strongly inhibited by an IL-6 receptor antibody (tocilizumab) and less well by TN

53 is study did not reveal any evidence that an IL-6 receptor antibody affects behavioral outcomes in sc

54 Inhibition of IL-6 signaling with the anti-IL-6 receptor antibody tocilizumab has provided some cli

55 purpose of this trial was to test whether an IL-6 receptor antibody, tocilizumab, would improve resid

56 immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids,

57 nt humanized monoclonal antibody against the IL-6 receptor approved for treatment of rheumatoid arthr

58 monoclonal antibodies targeting IL-6 and the IL-6 receptor are also being studied for the management

59 , an anti-inflammatory cytokine, and soluble IL-6 receptor are associated with systemic juvenile rheu

60 We show that IL-6 receptors are present in intestinal epithelia in a

61 IL-6 receptors are present on pituitary corticotrophs an

62 effect required NGF or NT-3 but not soluble IL-6 receptor as cofactors.

63 RI), IL-1RII, TNF receptor II (TNFR II), and IL-6 receptor as well as the level of proinflammatory cy

64 that sex steroids regulate expression of the IL-6 receptor as well.

65 was associated with a 2-4-fold reduction of IL-6 receptor at protein and mRNA levels in SGN-40-treat

66 neutralizing antibodies directed against the IL-6 receptor block Rac1-induced STAT3 activation.

67 e and immunoabsorption as well as subsequent IL-6 receptor blockade through tocilizumab, a complete a

68 sults from the recent clinical studies using IL-6 receptor blockade, and describe potential mechanism

69 he IL-1 receptor antagonist anakinra and the IL-6 receptor blocker tocilizumab.

70 uppressive function on the expression of the IL-6 receptor by T cells.

71 but failed to affect the mRNA expression of IL-6 receptor chains or activation of JAK2 and STAT3.

72 Furthermore, cholangiocytes possessed the IL-6 receptor complex subunits and intact signaling mech

73 e the nonsignaling gp80 alpha subunit of the IL-6 receptor complex.

74 ecifically mediated by signaling through the IL-6 receptor complex.

75 equential assembly of a functional hexameric IL-6 receptor complex.

76 ies against IL-6 or the gp130 subunit of the IL-6 receptor did not attenuate ET-1-induced collagen ac

77 mab; however, he had rapid improvement after IL-6 receptor-directed therapy with tocilizumab.

78 Since the IL-6 receptor does not contain binding sites for the p85

79 Anti-IL-6 antibodies or blocking the IL-6 receptors elicits reduced collagen synthesis, sugge

80 e found that IL-2 and TGF-beta down-regulate IL-6 receptor expression and IL-6 signaling.

81 IL-6 receptor expression in single osteoclasts was confi

82 ediated increases in transport by increasing IL-6 receptor expression on the cell surface.

83 roliferative disorders, viral IL-6 and human IL-6 receptor expression was examined.

84 ne representing the only site of unequivocal IL-6 receptor expression.

85 tentiation is likely due to the induction of IL-6-receptor expression as well as prolonged intensity

86 (vIL-6), which does not require the cellular IL-6 receptor for binding to the ubiquitously expressed

87 Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor

88 ion results in the induction of the IL-6 and IL-6 receptor genes and neutralizing antibodies directed

89 RNA of the signal-transducing subunit of the IL-6 receptor (gp130) in cells of the bone marrow stroma

90 ted by the signal-transducing subunit of the IL-6 receptor, gp130, or by co-transfected IL-3 receptor

91 By circumventing IL-6-receptor-gp130-coupled signaling with ectopic expre

92 data suggest tissue-specific differences in IL-6-receptor-gp130-coupled signaling, thereby limiting

93 We determined the role of IL-6-receptor-gp130-Stat3 signaling in IL-6 activation o

94 Stem-like and progenitor cells expressed the IL-6 receptor gp80 with concomitant expression of pSTAT3

95 dence that the ligand-binding subunit of the IL-6 receptor (gp80) is a limiting factor for the action

96 effect because IFN-alpha down-regulates the IL-6 receptor, gp80.

97 a humanized monoclonal antibody against the IL-6 receptor, has shown an excellent response.

98 s have been observed in association with the IL-6 receptor; however, inhibition of Src kinases by Csk

99 A functional amino acid change in the IL-6 receptor (IL-6R Asp358Ala; rs2228145) was significa

100 An antibody to the IL-6 receptor (IL-6R) alpha subunit effectively neutrali

101 Key substrates of ADAM17 are the IL-6 receptor (IL-6R) and TNF-alpha.

102 liminary results have been obtained with the IL-6 receptor (IL-6R) antagonist tocilizumab for the tre

103 L-6 can mediate proinflammatory effects, and IL-6 receptor (IL-6R) blockade as a treatment for inflam

104 The current study evaluated the effect of IL-6 receptor (IL-6R) blockade with an antiYIL-6R monocl

105 ly competes for binding to the cytokine with IL-6 receptor (IL-6R) by using side chains of two CDR re

106 FN-alpha growth-inhibited cell lines reduced IL-6 receptor (IL-6R) expression, IFN-alpha also reduced

107 A variant in the IL-6 receptor (IL-6R) gene increases asthma risk and is

108 d by membrane-bound and soluble forms of the IL-6 receptor (IL-6R) in processes called classic and tr

109 by way of antibody-mediated blockade of the IL-6 receptor (IL-6R) markedly reduces pathologic damage

110 ession in the normal liver, but both met and IL-6 receptor (IL-6R) mRNA are detectable; met mRNA is e

111 Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specif

112 Moreover, antibodies specific to the IL-6 receptor (IL-6R) or the gp130 subunit were capable

113 efined, nor has the behavior of the specific IL-6 receptor (IL-6R) or the signal transducer gp130.

114 a receptor complex consisting of the cognate IL-6 receptor (IL-6R) or the soluble IL-6 receptor (sIL-

115 Interleukin-6 (IL-6)/IL-6 receptor (IL-6R) plays a major role in autocrine/pa

116 This IL6R coding change increases IL-6 receptor (IL-6R) shedding and promotes IL-6 transsi

117 wth factor (IGF)/IGF-1 receptor (IGF-1R) and IL-6 receptor (IL-6R) signaling cascades, antiapoptotic

118 : classical signaling via its membrane-bound IL-6 receptor (IL-6R), and trans-signaling via a natural

119 e clinical usage of monoclonal antibodies to IL-6 receptor (IL-6R), designed to block IL-6 pathways.

120 would interact with the specific alpha-chain IL-6 receptor (IL-6R), is accessible and not occupied by

121 Expression of IL-6, IL-6 receptor (IL-6R), or glycoprotein 130, as well as I

122 Furthermore, we identified the IL-6 receptor (IL-6R), which mediates IL-6-dependent STA

123 pilot study of DES using a novel drug (anti-IL-6 receptor (IL-6R),Tocilizumab [TCZ]) + intravenous I

124 tocytes also do not show activation of other IL-6 receptor (IL-6R)-mediated Janus kinase substrates,

125 xamer, formed by the association of two IL-6.IL-6 receptor (IL-6R).gp130 trimers, with gp130 being th

126 nction in 2 ways: by directly binding to the IL-6 receptor (IL-6R; CD126) or via trans-signaling, in

127 is not dependent on the structurally related IL-6 receptor (IL-6R; gp80) subunit of the receptor-sign

128 hybridoma cell line, B9, and that the gp80 (IL-6 receptor [IL-6R]) component of the IL-6 receptor-si

129 Among these is tocilizumab (anti-IL-6 receptor [IL-6R]) which holds promise for modulatin

130 a role in cytokine signaling, including the IL-6 receptor, IL-1 receptor type I, and IL-1 receptor t

131 an ability of interferon-alpha and a soluble IL-6 receptor/IL-6 (sIL-6R alpha/IL-6) trans-signaling c

132 elated common variants in the interleukin-6 (Il-6) receptor (IL6R) gene to plasma C-reactive protein

133 We demonstrate a higher ratio of SOCS3 to IL-6 receptor in adult monocytes than in fetal monocytes

134 orms a complex with the gp130 subunit of the IL-6 receptor in an IL-6-dependent manner.

135 ially due to increased expression of soluble IL-6 receptor in the brain relative to the spinal cord t

136 Neutralizing autocrine IL-6 and/or blocking IL-6 receptors in IL-6(+)/gp80(+) MCL cells inhibited ce

137 ther oncostatin M (OSM) or IL-6 plus soluble IL-6 receptor increased the levels of p21 mRNA and prote

138 found that these cells synthesized IL-6 and IL-6 receptors; interruption of this pathway by IL-6 ant

139 The increased expression of IL-6 receptor is correlated with increased proliferation

140 The concentration of IL-6 receptor is increased eightfold in the prostate can

141 Signaling by the IL-6 receptor is mediated through the signal transducing

142 lobal IL-1 receptor gene knockout or central IL-6 receptor knockdown showed attenuated decrease in fo

143 ncrease: 2.3, 1.4-3.8, P = .001) and soluble IL-6 receptor level was associated within 6 years after

144 ptin binding and responded to leptin with an IL-6 receptor-like signaling that includes the activatio

145 these studies suggest that blocking IL-1 or IL-6 receptors may improve the regenerative capacity of

146 S) treated with the anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody tocilizumab.

147 Interleukin-6 (IL-6) and IL-6 receptor mRNA and protein have been reported in dif

148 Similarly, IL-6 receptor mRNA histostaining was increased in osteoc

149 se transcriptase-PCR analysis indicated that IL-6 receptor mRNA was present in all carcinoma cell lin

150 6 showed a significant reduction in IL-6 and IL-6 receptor mRNA, together with significant decreases

151 sed to study the effects of dexamethasone on IL-6 receptor number in the well-differentiated human he

152 Neutralization of IL-6 receptor on ECs abolished the ability of HCMV secre

153 Activated T cells expressed lower levels of IL-6 receptors on their surfaces, yet there were suffici

154 clast formation stimulated by IL-6 + soluble IL-6 receptor, oncostatin M, or IL-1 but not by parathyr

155 Either a blocking Ab to the IL-6 receptor or a neutralizing Ab to IL-6 significantly

156 blocked the ability of either IL-6 + soluble IL-6 receptor or oncostatin M to induce RANKL.

157 Hepatocyte-specific ablation of the IL-6 receptor or Stat3, a major downstream effector of I

158 y receptor-mediated (i.e., TNFalpha, NGF, or IL-6 receptor) or direct activation of protein kinase Ce

159 ceptor IL-6R (sIL-6R); by an antibody to the IL-6 receptor; or by minocycline, which inhibits the mic

160 It is likely that this upregulation of IL-6 receptors "primes" human liver cells for subsequent

161 DL1-mediated reduction in membrane (m)-bound IL-6 receptor (R) expression, converting progenitor cell

162 hich blocks leukocyte TNF, TNF receptor, and IL-6 receptor release, also inhibits L-selectin shedding

163 dependently of the gp80 alpha-subunit of the IL-6 receptor, required for hIL-6 signal transduction.

164 The level of soluble human IL-6 receptor (shuIL-6R) in murine serum and fluorescenc

165 STAT3 serves as the mediator of the IL-6 receptor signal and appears to contribute to the tr

166 aft proteins caveolin-1 and flotillin-1, the IL-6-receptor signal transducing chain gp130, the interf

167 p80 (IL-6 receptor [IL-6R]) component of the IL-6 receptor-signal transducer (gp180) complex plays a

168 al protein S6 kinase, respectively) and IL-6/IL-6 receptor signaling (i.e., IL-6 production and signa

169 Blocking IL-6 receptor signaling from Janus kinases to the Stat3

170 at there is activation-induced inhibition of IL-6 receptor signaling in T cells.

171 Activation of the IL-6 receptor signaling pathway may play a role in diffe

172 dentify TRAF5 as a negative regulator of the IL-6 receptor signaling pathway that limits the inductio

173 ory responses, its role in the regulation of IL-6 receptor signaling remains unclear.

174 or and are thus unable to respond to classic IL-6 receptor signaling.

175 ignaling-3 (SOCS-3), a negative regulator of IL-6 receptor signaling.

176 o investigate the role of the interleukin 6 (IL-6) receptor signaling in the pathogenesis of MCD and

177 c activation of STAT3 by T-cell receptor and IL-6 receptor signals.

178 though treatment with either IL-6 or soluble IL-6 receptor (sIL-6R) alone had no effect on VEGF produ

179 cognate IL-6 receptor (IL-6R) or the soluble IL-6 receptor (sIL-6R) and glycoprotein 130 (gp130).

180 Soluble forms of the IL-6 receptor (sIL-6R) bind to the cytokine IL-6 with si

181 tagonist of the interleukin-6 (IL-6)/soluble IL-6 receptor (sIL-6R) complex and selectively inhibits

182 IL-6 and soluble IL-6 receptor (sIL-6R) expression in induced sputum of a

183 ession; however, the addition of the soluble IL-6 receptor (sIL-6R) induced IL-6 transcripts.

184 s to evaluate the effect of IL-6 and soluble IL-6 receptor (sIL-6R) on hematopoietic and skeletal act

185 Surprisingly, soluble IL-6 receptor (sIL-6R) produced initial decrease of sEPS

186 al fibroblasts treated with IL-6 and soluble IL-6 receptor (sIL-6R) was used to probe a cytokine micr

187 hanced through transsignaling by the soluble IL-6 receptor (sIL-6r), allowing for the pleiotropic cyt

188 liver enzymes, interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), and soluble tumor necrosis facto

189 d respond to IL-6 in the presence of soluble IL-6 receptor (sIL-6R), but the cell surface expression

190 Expression of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10, and IL-13 was detected by

191 production of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10, and tumor necrosis factor

192 oteases and receptors, including the soluble IL-6 receptor (sIL-6R), were then quantitated.

193 d secreted significant levels of the soluble IL-6 receptor (sIL-6R).

194 -6 alone and in combination with the soluble IL-6 receptor (sIL-6R).

195 secretion of interleukin (IL)-6 and soluble-IL-6 receptor (sIL-6R).

196 dium of cytokine (TNF-alpha and IL-6/soluble IL-6 receptor)-stimulated human cartilage explants.

197 athecal treatment with antisense directed to IL-6 receptor subunit gp130 (gp130), but not to tumor ne

198 with colitis was increased 80-fold, and the IL-6 receptor subunits IL-6R alpha and gp130 were presen

199 Moreover, addition of soluble interleukin-6 (IL-6) receptor to the medium endowed IL-6 with the abili

200 hagy in myotubes when complexed with soluble IL-6 receptor (trans-signaling).

201 pression of IL-6 in combination with soluble IL-6 receptor was a reliable predictor of ALI in SAP.

202 s depleted from MSC conditioned media or the IL-6 receptor was blocked on tumor cells.

203 SHV-positive plasmablasts, whereas the human IL-6 receptor was expressed in most KSHV-positive cells.

204 Immunolabeling studies showed that the IL-6 receptor was restricted to the basal membrane of Pa

205 s phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be invo

206 1 and 2), as well as interleukin (IL)-6 and IL-6 receptor were measured on a daily, weekly and month

207 recruits microglial cells to provide soluble IL-6 receptor, which can form complexes with IL-6.

208 well as signaled by increased pSTAT3 via the IL-6 receptor, which inhibits IRS 1/2 phosphorylation.